Advaxis, Inc. (ADXS)
USD 0.03
(0.0%)
USD 0.03
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 8.31 Million USD | 69200.0% |
| 2022 | 12 Thousand USD | -70.0% |
| 2021 | 40 Thousand USD | -99.34% |
| 2020 | 6.01 Million USD | 1912.37% |
| 2019 | 299 Thousand USD | 0.0% |
| 2018 | - USD | 0.0% |
| 2017 | - USD | -100.0% |
| 2016 | 325.16 Million USD | 1100309.49% |
| 2015 | 29.54 Thousand USD | -53.01% |
| 2014 | 62.88 Thousand USD | -72.18% |
| 2013 | 226.01 Thousand USD | -52.64% |
| 2012 | 477.27 Thousand USD | -51.24% |
| 2011 | 978.87 Thousand USD | -31.95% |
| 2010 | 1.43 Million USD | -55.05% |
| 2009 | 3.19 Million USD | 463.24% |
| 2008 | 568.13 Thousand USD | 467.82% |
| 2007 | 100.05 Thousand USD | -98.19% |
| 2006 | 5.52 Million USD | 1003.18% |
| 2005 | 500.57 Thousand USD | -50.85% |
| 2004 | 1.01 Million USD | 0.0% |
| 2003 | - USD | 0.0% |
| 2002 | - USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 Q3 | 3.48 Million USD | 125.68% |
| 2023 Q2 | 1.54 Million USD | -7.28% |
| 2023 Q1 | 1.66 Million USD | -5.03% |
| 2023 FY | 8.31 Million USD | 69200.0% |
| 2023 Q4 | 8.31 Million USD | 138.97% |
| 2022 Q3 | 12 Thousand USD | -36.84% |
| 2022 FY | 12 Thousand USD | -70.0% |
| 2022 Q4 | 1.75 Million USD | 14491.67% |
| 2022 Q1 | 27 Thousand USD | -20.59% |
| 2022 Q2 | 19 Thousand USD | -29.63% |
| 2021 Q4 | 34 Thousand USD | -15.0% |
| 2021 Q3 | 40 Thousand USD | -92.03% |
| 2021 Q2 | 502 Thousand USD | -0.59% |
| 2021 FY | 40 Thousand USD | -99.34% |
| 2021 Q1 | 505 Thousand USD | -8.68% |
| 2020 Q2 | 534 Thousand USD | -2.55% |
| 2020 Q4 | 553 Thousand USD | -90.81% |
| 2020 FY | 6.01 Million USD | 1912.37% |
| 2020 Q1 | 548 Thousand USD | 83.28% |
| 2020 Q3 | 6.01 Million USD | 1026.78% |
| 2019 FY | 299 Thousand USD | 0.0% |
| 2019 Q4 | 299 Thousand USD | 0.0% |
| 2019 Q3 | - USD | 0.0% |
| 2019 Q2 | - USD | 0.0% |
| 2019 Q1 | - USD | 0.0% |
| 2018 Q2 | - USD | 0.0% |
| 2018 FY | - USD | 0.0% |
| 2018 Q1 | - USD | 0.0% |
| 2018 Q3 | - USD | 0.0% |
| 2018 Q4 | - USD | 0.0% |
| 2017 Q2 | 294.99 Thousand USD | -3.3% |
| 2017 Q1 | 305.04 Thousand USD | -3.19% |
| 2017 FY | - USD | -100.0% |
| 2017 Q4 | - USD | 0.0% |
| 2017 Q3 | - USD | -100.0% |
| 2016 Q1 | - USD | -100.0% |
| 2016 Q2 | 335.21 Thousand USD | 0.0% |
| 2016 Q4 | 315.1 Thousand USD | -99.9% |
| 2016 Q3 | 325.16 Million USD | 96899.85% |
| 2016 FY | 325.16 Million USD | 1100309.49% |
| 2015 Q3 | 29.54 Thousand USD | 0.0% |
| 2015 Q2 | 29.54 Thousand USD | 0.0% |
| 2015 FY | 29.54 Thousand USD | -53.01% |
| 2015 Q4 | 29.54 Thousand USD | 0.0% |
| 2015 Q1 | 29.54 Thousand USD | -53.01% |
| 2014 Q1 | 62.88 Thousand USD | -72.42% |
| 2014 Q3 | 62.88 Thousand USD | 0.0% |
| 2014 Q2 | 62.88 Thousand USD | 0.0% |
| 2014 Q4 | 62.88 Thousand USD | 0.0% |
| 2014 FY | 62.88 Thousand USD | -72.18% |
| 2013 FY | 226.01 Thousand USD | -52.64% |
| 2013 Q1 | 3.33 Million USD | 0.07% |
| 2013 Q2 | 3.57 Million USD | 7.0% |
| 2013 Q3 | 226.01 Thousand USD | -93.67% |
| 2013 Q4 | 227.97 Thousand USD | 0.87% |
| 2012 Q1 | 4.74 Million USD | 6.51% |
| 2012 Q2 | 395.56 Thousand USD | -91.66% |
| 2012 Q3 | 477.27 Thousand USD | 20.66% |
| 2012 Q4 | 3.33 Million USD | 598.6% |
| 2012 FY | 477.27 Thousand USD | -51.24% |
| 2011 FY | 978.87 Thousand USD | -31.95% |
| 2011 Q4 | 4.45 Million USD | 355.09% |
| 2011 Q1 | 4.66 Million USD | 102.01% |
| 2011 Q3 | 978.87 Thousand USD | -29.3% |
| 2011 Q2 | 1.38 Million USD | -70.31% |
| 2010 Q2 | 1.48 Million USD | -70.3% |
| 2010 FY | 1.43 Million USD | -55.05% |
| 2010 Q4 | 2.3 Million USD | 60.49% |
| 2010 Q3 | 1.43 Million USD | -3.41% |
| 2010 Q1 | 5.01 Million USD | 31.9% |
| 2009 Q2 | 1.89 Million USD | 80.92% |
| 2009 Q1 | 1.04 Million USD | 97.59% |
| 2009 Q4 | 3.8 Million USD | 18.81% |
| 2009 Q3 | 3.19 Million USD | 69.26% |
| 2009 FY | 3.19 Million USD | 463.24% |
| 2008 FY | 568.13 Thousand USD | 467.82% |
| 2008 Q2 | 73.51 Thousand USD | -8.43% |
| 2008 Q4 | 528.86 Thousand USD | -6.91% |
| 2008 Q3 | 568.13 Thousand USD | 672.79% |
| 2008 Q1 | 80.28 Thousand USD | -3.22% |
| 2007 Q4 | 82.94 Thousand USD | -17.1% |
| 2007 Q1 | 4.74 Million USD | 7.15% |
| 2007 Q2 | 3.76 Million USD | -20.6% |
| 2007 Q3 | 100.05 Thousand USD | -97.35% |
| 2007 FY | 100.05 Thousand USD | -98.19% |
| 2006 Q4 | 4.43 Million USD | -19.77% |
| 2006 Q3 | 5.52 Million USD | 99.33% |
| 2006 Q1 | 2.83 Million USD | 465.29% |
| 2006 Q2 | 2.77 Million USD | -2.29% |
| 2006 FY | 5.52 Million USD | 1003.18% |
| 2005 Q2 | 491.56 Thousand USD | 0.21% |
| 2005 Q4 | 501.58 Thousand USD | 0.2% |
| 2005 FY | 500.57 Thousand USD | -50.85% |
| 2005 Q3 | 500.57 Thousand USD | 1.83% |
| 2005 Q1 | 490.56 Thousand USD | 0.48% |
| 2004 FY | 1.01 Million USD | 0.0% |
| 2004 Q4 | 488.23 Thousand USD | 0.0% |
| 2003 FY | - USD | 0.0% |
| 2002 FY | - USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | 79.817% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | -101.749% |
| SQZ Biotechnologies Company | 27.47 Million USD | 69.728% |
| Evofem Biosciences, Inc. | 43.37 Million USD | 80.827% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | 72.063% |
| Mesoblast Limited | 118.7 Million USD | 92.994% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | -776.964% |
| Genus plc | 233.1 Million USD | 96.432% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | -183.785% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -518.942% |
| Marizyme, Inc. | 18.71 Million USD | 55.571% |
| ContraFect Corporation | 2.88 Million USD | -188.65% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | -1008.8% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -6037.858% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | -474.977% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | -257.531% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | -46.969% |
| MultiCell Technologies, Inc. | 202.58 USD | -4104944.921% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 57.48 Million USD | 85.535% |
| EV Biologics, Inc. | 1.49 Million USD | -456.347% |
| Q BioMed Inc. | 4.1 Million USD | -102.337% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | 74.877% |
| Neon Bloom, Inc. | 630.07 Thousand USD | -1219.839% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -577.0% |
| Biomind Labs Inc. | 735.54 Thousand USD | -1030.595% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 171.54 Million USD | 95.152% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | 36.016% |
| Skye Bioscience, Inc. | 4.61 Million USD | -80.185% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | -836.419% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -5776.284% |
| Arch Therapeutics, Inc. | 5.87 Million USD | -41.643% |
| IMV Inc. | 28.88 Million USD | 71.209% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -32234.072% |
| Curative Biotechnology, Inc. | 2.25 Million USD | -268.228% |
| GB Sciences, Inc. | 1.75 Million USD | -372.686% |
| Alpha Cognition Inc. | 1.22 Million USD | -581.432% |
| HST Global, Inc. | 98.31 Thousand USD | -8358.182% |
| CSL Limited | 12.18 Billion USD | 99.932% |
| Halberd Corporation | 150 Thousand USD | -5444.0% |
| Enzolytics Inc. | 996.33 Thousand USD | -734.657% |
| Resverlogix Corp. | 6.49 Million USD | -28.116% |
| Affymax, Inc. | - USD | -Infinity% |
| SYBLEU INC | 477.5 Thousand USD | -1641.571% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | -3153.623% |
| argenx SE | 20 Million USD | 58.42% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | 81.747% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -207.01% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 10.22 Thousand USD | -81230.073% |
| Genscript Biotech Corporation | 417.73 Million USD | 98.009% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | -4045.233% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | -246.829% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -3526.832% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | 87.706% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | -174.801% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -2211.862% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.32 Million USD | 59.091% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -5494.199% |
| BioStem Technologies, Inc. | 4.71 Million USD | -76.507% |
| ONE Bio Corp. | 19.71 Million USD | 57.819% |
| Reve Technologies, Inc. | 250.18 Thousand USD | -3223.98% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | -3243.519% |
| Agentix Corp. | 50 Thousand USD | -16532.0% |
| LadRx Corporation | 33.6 Thousand USD | -24645.581% |
| Cell Source, Inc. | 9.25 Million USD | 10.138% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -999.703% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -999.703% |
| NovAccess Global Inc. | 2.19 Million USD | -278.021% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | -17.577% |
| Itoco Inc. | 228.37 Thousand USD | -3541.347% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | -3841.699% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | -66.887% |
| Kadimastem Ltd | 891.22 Thousand USD | -833.097% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -1969.434% |
| CytoDyn Inc. | 30.07 Million USD | 72.35% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | 484.28 Thousand USD | -1617.174% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 351.84 Thousand USD | -2263.527% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | -6.343% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -6688.571% |
| Rebus Holdings, Inc. | 310 Thousand USD | -2582.581% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | -75.618% |
| International Stem Cell Corporation | 4.17 Million USD | -99.043% |
| Bioxytran, Inc. | 1.92 Million USD | -332.0% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -13224.147% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -281.31% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | 3.133% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | -434.626% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | -3002.985% |
| Neutra Corp. | 54.15 Thousand USD | -15255.639% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | -354.426% |
| PureTech Health plc | 25.51 Million USD | 67.404% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | -579.286% |
| IXICO plc | 472.02 Thousand USD | -1661.779% |
| IntelGenx Technologies Corp. | 15.5 Million USD | 46.352% |
| Gelesis Holdings, Inc. | 62.26 Million USD | 86.644% |
| CSL Limited | 12.18 Billion USD | 99.932% |
| Cellectis S.A. | 92.77 Million USD | 91.037% |